End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.85 EUR | -.--% | +1.19% | -58.33% |
May. 14 | Biophytis unveils design for obesity study | CF |
May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Sales 2024 * | - | Sales 2025 * | 4.8M 5.21M | Capitalization | 1.97M 2.14M |
---|---|---|---|---|---|
Net income 2024 * | -19M -20.61M | Net income 2025 * | -16M -17.35M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.41 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock